Clinical Cancer Research, Vol 3, Issue 10 1815-1822, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients

J Kos, B Stabuc, A Schweiger, M Krasovec, N Cimerman, N Kopitar-Jerala and I Vrhovec
Jozef Stefan Institute, Department of Biochemistry and Molecular Biology, 1000 Ljubljana, Slovenia.

The levels of cathepsins (Cats) B, H, and L and their inhibitors stefin A and cystatin C were determined in the sera of 43 patients with metastatic melanoma, in 54 patients with treated cutaneous melanoma with no evidence of metastatic disease, and in 30 healthy blood donors, using quantitative ELISAs. The levels of Cats B and H and cystatin C were significantly higher within the group of metastatic melanoma patients compared with the healthy controls. The median Cat B was 4.8 versus 3.6 ng/ml (P < 0.013), the median Cat H was 13.7 versus 4.9 ng/ml (P < 0.0001), and the median cystatin C was 470 versus 320 ng/ml (P < 0.02). Cat H was also significantly increased within the group of melanoma patients with no metastasis, with a median of 9.6 ng/ml. Cat B was found to correlate with Cat L (r = 0.36; P < 0.02) and cystatin C (r = 0.41; P < 0.008). The serum level of Cat H was significantly increased in patients showing no response to the chemoimmunotherapy as compared to the level in responders. Metastatic melanoma patients with high contents of Cat B and Cat H experienced significantly shorter overall survival rates than the patients with low levels of each enzyme (Cat B: P < 0.003 and relative risk, 2.5; Cat H: P < 0.006 and relative risk, 2.4, using medians as cutoff values). The other potential factors for prognosis for this group of patients revealed moderate (histological type and age) or no (tumor thickness, sex, and lymph node metastasis) prognostic significance. Similarly, no difference in survival was found for stefin A, cystatin C, and Cat L. These results suggest that the serum levels of Cats B and H could serve as prognostic factors for patients with advanced melanoma.

This article has been cited by other articles:

				M.-J. Lee, G.-R. Yu, S.-H. Park, B.-H. Cho, J.-S. Ahn, H.-J. Park, E.-Y. Song, and D.-G. Kim Identification of Cystatin B as a Potential Serum Marker in Hepatocellular Carcinoma Clin. Cancer Res., February 15, 2008; 14(4): 1080 - 1089. [Abstract] [Full Text] [PDF]

				T. Zavasnik-Bergant, U. Repnik, A. Schweiger, R. Romih, M. Jeras, V. Turk, and J. Kos Differentiation- and maturation-dependent content, localization, and secretion of cystatin C in human dendritic cells J. Leukoc. Biol., July 1, 2005; 78(1): 122 - 134. [Abstract] [Full Text] [PDF]

				E. J. Lamb, H. J. Stowe, D. E. Simpson, A. J. Coakley, D. J. Newman, and M. Leahy Diagnostic Accuracy of Cystatin C as a Marker of Kidney Disease in Patients with Multiple Myeloma: Calculated Glomerular Filtration Rate Formulas Are Equally Useful Clin. Chem., October 1, 2004; 50(10): 1848 - 1851. [Full Text] [PDF]

				J. P. Sokol and W. P. Schiemann Cystatin C Antagonizes Transforming Growth Factor {beta} Signaling in Normal and Cancer Cells Mol. Cancer Res., March 1, 2004; 2(3): 183 - 195. [Abstract] [Full Text] [PDF]

				A. Waghray, D. Keppler, B. F. Sloane, L. Schuger, and Y. Q. Chen Analysis of a Truncated Form of Cathepsin H in Human Prostate Tumor Cells J. Biol. Chem., March 22, 2002; 277(13): 11533 - 11538. [Abstract] [Full Text] [PDF]

				N. C. Levitt, F. A. L. M. Eskens, K. J. O'Byrne, D. J. Propper, L. J. Denis, S. J. Owen, L. Choi, J. A. Foekens, S. Wilner, J. M. Wood, et al. Phase I and Pharmacological Study of the Oral Matrix Metalloproteinase Inhibitor, MMI270 (CGS27023A), in Patients with Advanced Solid Cancer Clin. Cancer Res., July 1, 2001; 7(7): 1912 - 1922. [Abstract] [Full Text] [PDF]

				C. F. M. Sier, G. Casetta, J. H. Verheijen, A. Tizzani, V. Agape, J. Kos, F. Blasi, and R. Hanemaaijer Enhanced Urinary Gelatinase Activities (Matrix Metalloproteinases 2 and 9) Are Associated with Early-Stage Bladder Carcinoma: A Comparison with Clinically Used Tumor Markers Clin. Cancer Res., June 1, 2000; 6(6): 2333 - 2340. [Abstract] [Full Text]

				R. P. Woitas, B. Stoffel-Wagner, S. Flommersfeld, U. Poege, P. Schiedermaier, H.-U. Klehr, U. Spengler, F. Bidlingmaier, and T. Sauerbruch Correlation of Serum Concentrations of Cystatin C and Creatinine to Inulin Clearance in Liver Cirrhosis Clin. Chem., May 1, 2000; 46(5): 712 - 715. [Full Text] [PDF]

				J. Kos, M. Krasovec, N. Cimerman, H. J. Nielsen, I. J. Christensen, and N. Brünner Cysteine Proteinase Inhibitors Stefin A, Stefin B, and Cystatin C in Sera from Patients with Colorectal Cancer: Relation to Prognosis Clin. Cancer Res., February 1, 2000; 6(2): 505 - 511. [Abstract] [Full Text]

				D. Newman and J. Kos More on Cystatin C • One of the authors of the article cited above responds: Clin. Chem., May 1, 1999; 45(5): 718 - 719. [Full Text] [PDF]

				T. Strojnik, J. Kos, B. Zidanik, R. Golouh, and T. Lah Cathepsin B Immunohistochemical Staining in Tumor and Endothelial Cells Is a New Prognostic Factor for Survival in Patients with Brain Tumors Clin. Cancer Res., March 1, 1999; 5(3): 559 - 567. [Abstract] [Full Text] [PDF]

				J. Kos, B. Stabuc, N. Cimerman, and N. Brunner Serum Cystatin C, a New Marker of Glomerular Filtration Rate, Is Increased during Malignant Progression Clin. Chem., December 1, 1998; 44(12): 2556 - 2557. [Full Text] [PDF]